Market capitalization | $408.19m |
Enterprise Value | $152.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.52 |
P/S ratio (TTM) P/S ratio | 9.41 |
P/B ratio (TTM) P/B ratio | 1.78 |
Revenue growth (TTM) Revenue growth | 15.67% |
Revenue (TTM) Revenue | $43.38m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
9 Analysts have issued a Tango Therapeutics Inc forecast:
9 Analysts have issued a Tango Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 43 43 |
16%
16%
|
|
Gross Profit | 41 41 |
26%
26%
|
|
EBITDA | -137 -137 |
31%
31%
|
EBIT (Operating Income) EBIT | -140 -140 |
27%
27%
|
Net Profit | -123 -123 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Barbara Weber |
Employees | 140 |
Founded | 2017 |
Website | www.tangotx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.